ORGO Overview

Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.

Wall Street analysts forecast ORGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORGO is9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Organogenesis Holdings Inc revenue for the last quarter amounts to 37.23M USD, decreased -57.06

Organogenesis Holdings Inc. EPS for the last quarter amounts to -0.44 USD, increased 158.82

Organogenesis Holdings Inc (ORGO) has 854 emplpoyees as of June 21 2026.

Today ORGO has the market capitalization of 313.97M USD.